Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00509145 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)
A Phase 3 study of Multiple Sclerosis, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,106
- Enrollment target
- 20
- Study locations
NCT00509145 is a Phase 3 study of Multiple Sclerosis that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 1,106 participants, above the 582-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (90% higher). The trial reports 20 study locations across 17 states.
The verdict
NCT00509145, a Phase 3 study of Multiple Sclerosis, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,106 participants
- Enrollment target
- 20
- Study locations
Study Summary
Determination the efficacy of daily oral treatment with laquinimod 0.6 mg capsules as compared to placebo in subjects with Relapsing Remitting Multiple Sclerosis (RRMS).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Laquinimod
Study Locations (20)
Colorado
- Teva Investigational Site 1090 - Centennial
- Teva Investigational Site 1088 - Fort Collins
New York
- Teva Investigational Site 1082 - New York
- Teva Investigational Site 1079 - Rochester
Pennsylvania
- Teva Investigational Site 1100 - Hershey
- Teva Investigational Site 1087 - Philadelphia
Arizona
- Teva Investigational Site 1076 - Phoenix
Connecticut
- Teva Investigational Site 1094 - New Haven
Illinois
- Teva Investigational Site 1102 - Northbrook
Indiana
- Teva Investigational Site 1081 - Fort Wayne
Iowa
- Teva Investigational Site 1083 - Des Moines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,106 participants |
| Start Date | 2007-11-13 |
| Est. Completion | 2010-11-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00509145
The ClinicalTrials.gov registry entry for NCT00509145 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,106 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 582-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (90% higher). The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00509145 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Colorado, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00509145 about?
NCT00509145 is a clinical study titled "Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)". Determination the efficacy of daily oral treatment with laquinimod 0.6 mg capsules as compared to placebo in subjects with Relapsing Remitting Multiple Sclerosis (RRMS).
What is the current status of trial NCT00509145?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,106 participants. The study started on 2007-11-13. Estimated completion is 2010-11-08.
What conditions does trial NCT00509145 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT00509145?
The interventions under investigation include: Placebo (OTHER), Laquinimod (DRUG).
Who is sponsoring clinical trial NCT00509145?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00509145 being conducted?
This trial has 20 study locations across Arizona, Colorado, Connecticut, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
RECRUITING · Phase 3
-
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
RECRUITING · Phase 3
-
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.